Astria Therapeutics (ATXS)
(Real Time Quote from BATS)
$9.64 USD
+0.10 (1.05%)
Updated May 20, 2024 01:12 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Astria Therapeutics, Inc. [ATXS]
Reports for Purchase
Showing records 41 - 60 ( 66 total )
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
It''s The Final Countdown (Queue The 80s Soundtrack) - 3Q22 Highlights
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Our Sights Are Set on Upcoming Data; STAR-0215 Phase 1a Preliminary Data Readout On Track for YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Window of Opportunity Opens Further For STAR-0215 With Recent Landscape Updates
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
R&D Day Highlights; Big Step in Building STAR-0215 Profile Shortly
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looking Into the STAR(-0215) Data - R&D Day Takeaways
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Takeaways - HAE & The Changing Therapeutic Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Time to Step Up for These Catalysts; Making Real Differences
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Phase 1a Study of STAR-0215 Begins Clinical Evaluation; Updates Expected At Upcoming R&D Day
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Wishing On a STAR(-0215) - Looking Ahead to YE22 Data
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STAR-0215 Initiates First-in-Human Clinical Trial; Preliminary Phase 1a Results by YE22 Represent Important Driver
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IND Clearance Brings STAR-0215 One Step Closer to Clinical Proof-of-Concept as Important Driver
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STAR-0215 Delivers Prolonged Activity in Monkeys; Phase 1a Clinical Trial on the Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Results Out of Lanadelumab Pediatric Study Are Promising Indicator for STAR-0215 Treatment Reach
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; STAR-0215 Close Clinical Development; IND Submission Mid-2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Execution Is Always A Good Thing - Efforts On Track In 1Q22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Clinical Development Plans Make Us Starry-Eyed; STAR-0215 Phase 1a Study Coming Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J